Goodwin, K&L Gates Steer $1.5B Repligen Gene Therapy Deal
Repligen said Wednesday it will acquire BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, expanding its presence in the fast-growing cell and gene therapy market, with Goodwin Procter...To view the full article, register now.
Already a subscriber? Click here to view full article